title: Bowenoid Actinic Keratosis and Bowen's Disease Treated Successfully with Ingenol Mebutate.
abstract: Ingenol mebutate (IM) is a topical pharmacotherapy approved in Switzerland since 2012 for treating non-hypertrophic, non-hyperkeratotic actinic keratosis (AK). We report 2 cases with off-label use of IM. The first case of bowenoid AK was treated with 150 μg IM for 3 consecutive days with an almost complete clinical remission of the lesion. The second case of Bowen's disease was treated with 500 μg IM for 2 consecutive days leading to complete clinical remission.
authors: Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
authors: Mosab T
authors: MT
authors: Mohanna
authors: Günther F L
authors: GF
authors: Hofbauer
mesh_terms: D000279:Administration, Cutaneous; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001913:Bowen's Disease / Q000188:drug therapy* / Q000473:pathology; D004224:Diterpenes / Q000008:administration & dosage*; D005143:Eyelids; D005260:Female; D005782:Gels; D006225:Hand; D006801:Humans; D055623:Keratosis, Actinic / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: C486592:3-ingenyl angelate; D000970:Antineoplastic Agents; D004224:Diterpenes; D005782:Gels